SA
RXRX icon

Sanctuary Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Sanctuary Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.2K Sell
10,963
-1,383
-11% -$4.6K ﹤0.01% 2782
2026
Q1 		$37.9K Buy
12,346
+1,858
+18% +$7.18K ﹤0.01% 2505
2025
Q4 		$42.9K Sell
10,488
-2,667
-20% -$13.2K ﹤0.01% 2389
2025
Q3 		$64.2K Sell
13,155
-1,993
-13% -$10.5K ﹤0.01% 2372
2025
Q2 		$76.6K Buy
15,148
+4,653
+44% +$22.9K ﹤0.01% 2285
2025
Q1 		$55.5K Sell
10,495
-1,989
-16% -$14.5K ﹤0.01% 2138
2024
Q4 		$96K Sell
12,484
-1,014
-8% -$6.82K ﹤0.01% 2320
2024
Q3 		$76.9K Buy
+13,498
New +$96.8K ﹤0.01% 2327

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sanctuary Advisors's RXRX Position: Q2 2026 in Review

Sanctuary Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 11% in Q2 2026, selling an estimated $4.6K and leaving 10,963 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

Sanctuary Advisors first reported a position in RXRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $96K in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Sanctuary Advisors held 10,963 shares of Recursion Pharmaceuticals worth $40.2K as of Q2 2026.
  • Sanctuary Advisors sold 1,383 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2782 holding.
  • Sanctuary Advisors first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sanctuary Advisors's Recursion Pharmaceuticals position peaked at $96K in Q4 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.